Fair Value Calculator Fair Value Calculator
EN DE

GENESYS (GENESYS) Fair Value & Analysis

Technology · Market cap ₹14.0B

G GENESYS GENESYS · NSE
Price₹335.80
Fair Value₹155.90
Upside-53.6%
Quality33/100
Watch GENESYS for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹116.93 – ₹194.88

Fair value as of: Jul 3, 2026

From 17 valuation models · updated today

Share price +25.5% over the past month.

Price vs Fair Value (12 months)

₹666.20 ₹201.30 Fair Value ₹155.90 Jul 2025 Jul 2026

12‑month range ₹201.30 – ₹666.20 · fair‑value band ₹116.93 – ₹194.88 · the ₹335.80 price screens above the ₹155.90 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

GENESYS (GENESYS) currently trades at ₹335.80, while our model-based Fair Value estimate is ₹155.90 — implying the stock looks roughly 53.6% overvalued today. We read business quality at 33/100 (below-average quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, GENESYS generated revenue of ₹3.3B at a net margin of 9.9%. Revenue grew 10.7% year over year. It earns a return on equity of 5.2%. Net debt stands at ₹691M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) ₹3.3B
Revenue growth (YoY) +10.7%
Net margin 9.9%
Return on equity 5.2%
Free cash flow −₹44.4M FY2026
P/E ratio 42.5
More key figures
Operating margin 16.3%
EPS (TTM) ₹7.90
EPS growth (YoY) -35.9%
Net debt ₹691M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

GENESYS reported revenue of ₹3.3B in FY2026 versus ₹1.2B in FY2022, a compound +29.5%/yr. Reported net income was ₹326M in FY2026, compounding +24.8%/yr from FY2022.

Revenue +29.5%/yr
FY22 ₹1.2B
FY23 ₹1.8B
FY24 ₹2.0B
FY25 ₹3.1B
FY26 ₹3.3B
Net income +24.8%/yr
FY22 ₹134M
FY23 ₹191M
FY24 ₹221M
FY25 ₹562M
FY26 ₹326M

Is GENESYS fairly valued? → Check now

Similar stocks

6 more Software - Application stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock Price Fair Value vs Fair Value
SAP SE SAPP34 R$949.05 R$674.65 -29%
Salesforce, Inc CRM $188.75 $178.06 -6%
Uber Technologies, Inc UBER $68.61 $88.21 +29%
Shopify Inc SHOP $107.98 $32.94 -69%
ServiceNow, Inc NOW $93.01 $76.44 -18%
Cadence Design Systems, Inc CDNS $385.13 $80.41 -79%

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is GENESYS (GENESYS) undervalued?
As of Jul 3, 2026, our model estimates a fair value of ₹155.90 versus a price of ₹335.80 — about −54% (overvalued). Model-based estimate, not financial advice.
What is the fair value of GENESYS?
Our model-based fair value for GENESYS is ₹155.90 (as of Jul 3, 2026), built from audited fundamentals. The current price is ₹335.80.
What is the quality score of GENESYS?
GENESYS has a Quality Score of 33/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of GENESYS (GENESYS)?
GENESYS reported trailing-twelve-month revenue of about ₹3.3B (latest available figure, as of Jul 3, 2026).
What is the net profit margin of GENESYS?
The net profit margin of GENESYS is about 9.9%, meaning it keeps roughly 9.9% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.